Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES L LUDIVICO

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1750439147
CMS profile
170048
Location
FOUNTAIN HILL, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,204.51

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,184.82 70
Education $19.69 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES L LUDIVICO

NPI 1750439147 · CMS profile ID 170048

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

FOUNTAIN HILL, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750439147?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES L LUDIVICO, NPI 1750439147, CMS profile ID 170048. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750439147?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHARLES L LUDIVICO, NPI 1750439147, CMS profile ID 170048. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750439147?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHARLES L LUDIVICO, NPI 1750439147, CMS profile ID 170048, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1750439147?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $1,204.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $15.6104/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795403719 CMS
Genentech USA, Inc. $13.4203/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835896105 CMS
GlaxoSmithKline, LLC. $17.7203/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802619689 CMS
AbbVie Inc. $3.9303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795403713 CMS
Alexion Pharmaceuticals, Inc. $21.4903/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783112427 CMS
Lilly USA, LLC $19.5503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819004269 CMS
PFIZER INC. $12.1303/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833508479 CMS
Oxford Immunotec USA Inc $24.0903/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853735239 CMS
AbbVie Inc. $19.1703/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795403707 CMS
E.R. Squibb & Sons, L.L.C. $14.1303/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783595393 CMS
Novartis Pharmaceuticals Corporation $13.6903/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813039769 CMS
Janssen Biotech, Inc. $21.6302/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788641057 CMS
Amgen Inc. $5.8802/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826310919 CMS
Novartis Pharmaceuticals Corporation $13.6901/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813039765 CMS
AbbVie Inc. $15.8501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795403701 CMS
E.R. Squibb & Sons, L.L.C. $20.4501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783595383 CMS
Amgen Inc. $10.2401/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825213399 CMS
E.R. Squibb & Sons, L.L.C. $15.0501/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783595377 CMS
AbbVie Inc. $17.5901/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795403695 CMS
AbbVie Inc. $18.2801/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795403689 CMS
GlaxoSmithKline, LLC. $17.0101/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801694757 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28,130.32 143
PY2020 $3,453.52 100
PY2021 $1,204.51 71
PY2022 $932.11 50
PY2023 $1,459.23 75
PY2024 $1,256.70 72
PY2025 $1,724.90 73

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $35,485.35 26
PY2024 Principal investigator $7,716.40 2
PY2023 Principal investigator $15,683.41 3
PY2022 Recipient $329.00 2
PY2022 Principal investigator $33,773.97 11
PY2021 Principal investigator $68,982.09 30
PY2020 Recipient $964.60 2
PY2020 Principal investigator $139,112.04 35
PY2019 Recipient $1,384.97 1
PY2019 Principal investigator $211,493.09 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ARGENX US, INC. $512.00 11/20/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149725
Principal investigator 1 ARGENX US, INC. $4,835.00 11/20/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149745
Principal investigator 1 ARGENX US, INC. $1,500.00 10/24/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149749
Principal investigator 1 ARGENX US, INC. $52.00 10/22/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149733
Principal investigator 1 ARGENX US, INC. $52.00 10/22/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149737
Principal investigator 1 ARGENX US, INC. $1,420.00 10/20/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149753
Principal investigator 1 ARGENX US, INC. $1,353.00 10/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149718
Principal investigator 1 ARGENX US, INC. $2,661.00 10/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149721
Principal investigator 1 ARGENX US, INC. $512.00 10/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149729
Principal investigator 1 ARGENX US, INC. $1,459.00 10/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149741
Principal investigator 1 ARGENX US, INC. $95.50 09/03/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149805
Principal investigator 1 ARGENX US, INC. $0.70 09/03/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149808
Principal investigator 1 ARGENX US, INC. $51.75 09/03/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149812
Principal investigator 1 ARGENX US, INC. $3,530.00 08/13/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149785
Principal investigator 1 ARGENX US, INC. $5,204.00 08/13/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149788
Principal investigator 1 ARGENX US, INC. $7,000.00 07/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149793
Principal investigator 1 ARGENX US, INC. $1,061.00 07/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149797
Principal investigator 1 ARGENX US, INC. $2,034.00 07/02/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149800
Principal investigator 1 ARGENX US, INC. $159.00 06/18/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149757
Principal investigator 1 ARGENX US, INC. $75.20 06/18/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149762
Principal investigator 1 ARGENX US, INC. $764.00 06/18/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149767
Principal investigator 1 ARGENX US, INC. $11.20 06/18/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149771
Principal investigator 1 ARGENX US, INC. $51.75 06/18/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149775
Principal investigator 1 ARGENX US, INC. $71.60 06/18/2025 Non-covered Recipient Entity
East Penn Rheumatology Associates, P.C.
Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome No dispute reported 06/30/2026 1237149781
Principal investigator 1 Eli Lilly and Company $7.65 05/08/2025 Non-covered Recipient Entity
EAST PENN RHEUMATOLOGY ASSOCIATES PC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883908
Principal investigator 1 Eli Lilly and Company $1,012.00 05/06/2025 Non-covered Recipient Entity
EAST PENN RHEUMATOLOGY ASSOCIATES PC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187879983